There is much debate surrounding the potential impact on the UK’s life sciences industry of the country’s decision to leave the European Union. Here, IQVIA analysis posits ‘upside’ and ‘downside’ Brexit scenarios on pharmaceutical market sales and growth in the UK in comparison to a theoretical ‘No Brexit’ scenario.
Different forms of Brexit will have differing levels of impact on UK Pharma. Here, PwC analysis outlines the impacts of the UK being: an European Economic Area (EEA) member, having a free trade agreement (FTA) with the EU, entering into a bilateral integration treaty with the EU, and not establishing any new trade agreement with the EU.
A 2018 IQVIA survey found global life science leaders worried about the impact of Brexit on the UK’s continuing attractiveness as an investment destination.